Dupixent nears EU approval for COPD, as FDA delays

[cafead]

via Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chronic obstructive pulmonary disease (COPD).

article source